AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investing in dividend stocks allows you to earn dividend income, the best passive income stream. In August, we (my wife and I) received a dividend income total of $1,415.47. 2023 was up 24%. Eight months down in 2024 and the S&P 500 is still up 14%, despite the recent sell-offs. Unemployment is starting to tick up recently.
AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.
AbbVie's leadership and revenue mix have changed, and more change is coming. There's a good chance that it will diversify into a new pharmaceutical segment.
AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem.
Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.
AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 then to around $195 now - vs. an increase of about 50% for the S&P 500 over this period.
These two companies sell products that remain in high demand even during recessions. They also have excellent dividend track records -- and one of them is a Dividend King.
Historically, September is a relatively bad month for stock markets. AT&T offers a huge dividend yield and it could start raising the payout again next year.
Consumers are still spending money on healthcare and fast-casual dining. AbbVie is a faithful dividend payer with a blockbuster portfolio.